- A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis.
- The purpose of this study is to determine whether the use of the study drug, secukinumab, can help treat patients who have non-radiographic ankylosing spondylitis. This study is currently actively enrolling. Further information is available at www.clinicaltrials.gov.
- Escalating the dose of Cosentyx is currently one approach for treating certain rheumatologic conditions.
- The purpose of this study is to discover if it is beneficial to double the standard dose of the biologic drug Cosentyx for patients with Ankylosing Spondylitis (AS). Patients with an AS diagnosis who have not responded to one biologic drug therapy or who have never been on a biologic, for whom other treatments (such as with NSAIDs) are not effective are invited to contact the study team to see if they could benefit from participating in this study. Further study details can be found by following this link: https://clinicaltrials.gov/ct2/show/NCT03350815?term=03350815&rank=1
- Treating Giant Cell Arteritis
- Currently many patients with a diagnosis of Giant Cell Arteritis (GCA) are on steroid therapy to help manage their disease.
- This study aims to explore the ability of biologic drug Kevzara to reduce the overall steroid exposure and help patients attain remission. Patients who have GCA and are interested in being a part of this study are invited to contact the study team to see if they qualify. Further study details can be found by following this link: https://clinicaltrials.gov/ct2/show/NCT03600805?term=03600805&rank=1
- Early Prevention of Psoriatic Arthritis joint damage
- This study aims to explore the efficacy of the drug Apremilast in treating early stages of Psoriatic arthritis (PsA) with limited joint involvement. Apremilast currently is used as an effective treatment for PsA at later stages of disease activity.
- This study will determine whether the drug is also effective at preventing joint involvement and further progression of the disease. Patients who have a recent diagnosis of PsA (2 years or less) that are interested in participating in the study are encouraged to contact the study team to see if they qualify. Further study details can be found by following this link: https://clinicaltrials.gov/ct2/show/NCT03747939?term=03747939&rank=1
- Psoriatic Arthritis and MRI outcomes
- This study explores the effectiveness of the drug Apremilast when used to prevent progression of Psoriatic arthritis (PsA). It will measure outcomes using MRI results as evidence of slowing or stopping disease activity. Patients who have a diagnosis of PsA made within the prior 5 years are invited to contact the study team to see if they qualify for enrollment in this study. Further study details can be found by following this link: https://clinicaltrials.gov/ct2/show/NCT03783026?term=03783026&rank=1
Physicians and patients are welcome to contact us for more information.
The principal investigator, Dr. Michael Bubb, can be reached at the rheumatology office, 352.294.8202.